Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141773

registered interest
date	24/07/2019
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Visas: Applications
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, if he will publish the service specification, including key performance indicators, agreed with Sopra Steria Limited (SSL) in respect of the contract for UK Visa and Citizenship Application Services.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	281733
answer	answer is ministerial correction date of answer 03/09/2019 answer text <p>The contract with Sopra Steria Limited (SSL) has been published and can be found using the following link - <a href="https://www.contractsfinder.service.gov.uk/Notice/ec5031ea-021e-471a-86cf-af540e8d8efa%20" target="_blank">https://www.contractsfinder.service.gov.uk/Notice/ec5031ea-021e-471a-86cf-af540e8d8efa</a></p><p><a href="https://www.contractsfinder.service.gov.uk/Notice/ec5031ea-021e-471a-86cf-af540e8d8efa%20" target="_blank"> </a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/09/2019 16:35:41 answering member 4455 label Biography information for Seema Kennedy
tabling member	4036 label Biography information for Luciana Berger

1141778

registered interest
date	24/07/2019
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Visas: Applications
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, for what reasons visa applicants are unable to access a local rate 0330 number to contact UK Visa and Citizenship Application Services until they have succeeded in making such an application; what estimate his Department has made of the number of people who have had to use the premium rate telephone number; and how much revenue was received in revenue from that premium rate number in the last 12 months.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	281734
answer	answer is ministerial correction date of answer 03/09/2019 answer text <p>The Home Office holds limited information relating to the number of customers who have used the premium line number to contact the UK Visa and Citizenship Application Services. In total, 13937 calls have been made to 0900 premium line number from the start of the UKVCAS contract in November 2018. This represents 5% of UKVCAS customers who made an application during this time period. The Home Office does not hold details of the revenue generated through calls made to the premium rate number.</p><p>The premium line referenced is an optional added value service, which offers general support to customers, before, during and after their appointment and assists them in finding information and choosing which Service Point to attend. The service utilises a premium rate (09) telephone number, registered with Ofcom and offers full cost transparency. Customers who do not wish to avail themselves of this chargeable service, may also contact SSL via their website, where they can choose from two options “make an enquiry” or “make a complaint”. Once an appointment has been booked a ‘0330’ number is provided to customers to support with appointment-related queries. The ‘0330’ number is not for general queries relating to the service.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/09/2019 16:18:24 answering member 4455 label Biography information for Seema Kennedy
tabling member	4036 label Biography information for Luciana Berger

1141779

registered interest
date	24/07/2019
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Visas: Applications
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, when his Department has had meetings with Sopra Steria Ltd on the UK Visa and Citizenship Application Services in the last 12 months; and what was discussed at those meetings.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	281735
answer	answer is ministerial correction date of answer 03/09/2019 answer text <p>The Home Office regularly meets with Sopra Steria Ltd to discuss a range of issues however the content of these discussions is commercially sensitive and therefore we are unable to disclose this information.</p><p>The contract has, within the terms and conditions, a schedule that specifically covers the governance and contract management of the service operation. This is set out in schedule 8 of the contract and can be found using the following link - <a href="https://www.contractsfinder.service.gov.uk/Notice/Attachment/a2ace827-80ca-46df-9fa3-e8eeec62519a" target="_blank">https://www.contractsfinder.service.gov.uk/Notice/Attachment/a2ace827-80ca-46df-9fa3-e8eeec62519a</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/09/2019 16:07:57 answering member 4455 label Biography information for Seema Kennedy
tabling member	4036 label Biography information for Luciana Berger

1141780

registered interest
date	24/07/2019
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Visas: Applications
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, if he will undertake a full review of the service and performance of Sopra Steria Ltd regarding the UK Visa and Citizenship Application Services.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	281736
answer	answer is ministerial correction date of answer 03/09/2019 answer text <p>The contract with Sopra Steria for the provision of Front End Services contains clauses and performance measures (KPIs) designed to ensure the timeliness and quality of service provision.</p><p>This also includes the contract management and governance schedule as described above supported by a dedicated Supplier Management Team with responsibility for ensuring the provider delivers to the required performance standards set out in the contract.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/09/2019 16:08:12 answering member 4455 label Biography information for Seema Kennedy
tabling member	4036 label Biography information for Luciana Berger

1141782

registered interest
date	24/07/2019
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Visas: Applications
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, which organisations his Department has advertised information to outlining that visa applicants wishing to extend their leave to remain will not be penalised in cases where they have had to wait for an appointment at a UK Visa and Citizenship Application Services service point; and how that information has been publicised.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	281737
answer	answer is ministerial correction date of answer 03/09/2019 answer text <p>Information about biometric enrolment timescales for UKVCAS customers is publicised to applicants as part of the online application process on GOV.UK.</p><p>If the applicant does not enrol biometrics within this period they are sent a reminder and are given a further period in which to enrol.</p><p>If the applicant does not enrol their biometrics within these timescales their application is deemed as invalid and could be rejected. Prior to any action to reject the application UKVI would check to confirm whether an appointment to enrol has been booked. UKVI would not reject an application because the applicant had to wait for an appointment</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/09/2019 16:06:28 answering member 4455 label Biography information for Seema Kennedy
tabling member	4036 label Biography information for Luciana Berger

1140957

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the side-effects of the drug metamizole.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280288
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280289 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1140958

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Spain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will have discussions with his Spanish counterpart on the effect of dispensing metamizole to (a) UK and (b) Spanish residents in Spain.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280289
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280290 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1140960

registered interest
date	22/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Metamizole: Spain
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to raise awareness of the potential side-effects of the drug metamizole among UK citizens and tourists in Spain.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	280290
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 280288 280289 question first answered 25/07/2019 16:07:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

1135177

registered interest
date	27/06/2019
answering body	Ministry of Housing, Communities and Local Government
answering dept id	7
answering dept short name	Housing, Communities and Local Government
answering dept sort name	Housing, Communities and Local Government
hansard heading	Garden Communities
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Housing, Communities and Local Government,with reference to the Loneliness Strategy, what steps he is taking to work with Homes England to incorporate community cohesion as part of the support offered to existing and future garden communities.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	270355
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>Across England, we are currently supporting 48 locally-led garden communities, to be exemplars of high quality, good design and best practice.</p><p>These places will encourage strong social connections through vibrant spaces with mixed community use and healthy places that take a holistic approach to tackling wellbeing priorities. To date we have provided £38 million in capacity funding which includes early support to fund dedicated staff teams, key studies and assessments to underpin delivery of our garden towns and villages.</p><p>My Department and Homes England are exploring an effective means of sharing learning and good practice on tackling loneliness and social isolation through design and planning approaches with professional and accredited bodies.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 02/07/2019 14:38:11 answering member 4495 label Biography information for Kit Malthouse
tabling member	4036 label Biography information for Luciana Berger

1123716

registered interest
date	29/04/2019
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Surveillance: Cameras
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, by what date the updated guidelines for the Surveillance Camera Code of Conduct will be published.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	248657
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The Government committed in the Home Office Biometrics Strategy 2018 to review the Surveillance Camera Code of Practice and it will be updated in due course.</p> answering member constituency North West Hampshire answering member printed Kit Malthouse question first answered 09/09/2019 13:49:33 answering member 4495 label Biography information for Kit Malthouse
tabling member	4036 label Biography information for Luciana Berger